Literature DB >> 12527628

Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases.

Kevin W Garey1, Anita Alwani, Larry H Danziger, Israel Rubinstein.   

Abstract

It is well established that macrolide antibiotics are efficacious in treating sinopulmonary infections in humans. However, a growing body of experimental and clinical evidence indicates that they also express distinct salutary effects that promote and sustain the reparative process in the chronically inflamed upper and lower respiratory tract. Unlike the anti-infective properties, these distinct effects are manifested at lower doses, usually after a relatively prolonged period (weeks) of treatment, and in the absence of an identifiable, viable pathogen. Long-term, low-dose administration of macrolide antibiotics has been used most commonly for sinusitis, diffuse panbronchiolitis, asthma, bronchiectasis, and cystic fibrosis. It is associated with down-regulation of nonspecific host inflammatory response to injury and promotion of tissue repair. Although large-scale trials are lacking, the prolonged use of these drugs has not been associated with emergence of clinically significant bacterial resistance or immunosuppression. Long-term, low-dose administration of 14- and 15-membered ring macrolide antibiotics may represent an important adjunct in the treatment of chronic inflammatory sinopulmonary diseases in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527628     DOI: 10.1378/chest.123.1.261

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Antibiotics in asthma.

Authors:  David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

2.  Antibiotic use in the management of pulmonary nodules.

Authors:  Saira Khokhar; Svetlana Mironov; Venkatraman E Seshan; Diane E Stover; Rohit Khirbat; Marc B Feinstein
Journal:  Chest       Date:  2009-09-25       Impact factor: 9.410

3.  Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Authors:  A Clement; A Tamalet; E Leroux; S Ravilly; B Fauroux; J-P Jais
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

4.  Update on infection and antibiotics in asthma.

Authors:  Donald R Rollins; David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

Review 5.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

Review 6.  Pharmacologic management of chronic rhinosinusitis, alone or with nasal polyposis.

Authors:  M Boyd Gillespie; J David Osguthorpe
Journal:  Curr Allergy Asthma Rep       Date:  2004-11       Impact factor: 4.919

Review 7.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

8.  Modified inflammation-based score as an independent malignant predictor in patients with pulmonary focal ground-glass opacity: a propensity score matching analysis.

Authors:  Long Jiang; Shanshan Jiang; Yongbin Lin; Han Yang; Zerui Zhao; Zehua Xie; Yaobin Lin; Hao Long
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

9.  Low-dose, long-term macrolide therapy in asthma: An overview.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Clin Mol Allergy       Date:  2004-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.